Abstract
Aim: The current study aims to co-deliver docetaxel (DTX) and alpha-lipoic acid (ALA) using solid lipid nanoparticles (SLNs) as a carrier for the treatment of breast cancer. Methods: Computational analysis was used to screen different solid lipids as carriers, following which SLNs were prepared and characterized. Furthermore, antioxidant activity assays and cell culture studies were performed. Results:In vitro assessment in 4T1 (murine mammary carcinoma) and MCF-7 (human breast adenocarcinoma)cells revealed enhanced efficacy of the co-loaded SLNs as compared with free drugs and single drug-loaded SLNs. Increased apoptosis following treatment with DTX-ALAco-loaded SLN was also observed. Conclusion: The developed SLNs showed significantly higher uptake efficiency along with improved cytotoxic and apoptotic potential indicating the usefulness of this combination.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
